"Reading Alkon's papers is like following a scientific detective story, where the truth turned out to surprise everyone, the principal researcher included."
Well put Boogins. The more Dr. Alkon and his team at BRNI uncovered the biochemical mechanism of Bryostatin's efficacy the more astounded they were that in addition to stimulating PKCe and synaptic regeneration it also reduced amyloid plaque and tau tangles.
Dr. Alkon said as much at the Bio CEO Investor Conference. At minute 17:06 he says “something that we couldn’t anticipate, in addition,(of Bryostatin’s stimulation of PKCe and synaptogenesis) is it takes care of the degenerative changes of toxic soluble A Beta Amyloids and toxic Tau.”
Boogins, though this would be potentially such a major breakthrough if successful, I think FDA would be hard pressed to consider approving a mass scale therapeutic space drug without at least one large scale confirmatory pivotal trial. I think they would consider only requiring one, but, that they would require one. I agree the research by Dr. Alkon is very interesting to get into and through.
News 
Market Data 
Discover 
AI
